Stefano Emili, MD
Nephrology · Anchorage, AKNPI 1558319434
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,457 of the $1,654 with a category attached, or 88.1%. It is spread thinly across 18 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $399 and has fallen 57.4% since, to $170 in 2025.
Across 73 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$335
- Amgen$221
- Pfizer$219
- AstraZeneca$181
- Otsuka America Pharmaceutical, Inc.$126
- Teleflex LLC$118
- plus $453 from 12 others
What the payments were for
- Food & beverage$1,45788%
- Education$19712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $335 |
| Amgen(2 entities) | 7 | $221 |
| Pfizer | 11 | $219 |
| AstraZeneca(2 entities) | 5 | $181 |
| Otsuka America Pharmaceutical, Inc. | 4 | $126 |
| Teleflex LLC | 1 | $118 |
| Bayer | 4 | $90 |
| Travere Therapeutics, Inc. | 10 | $87 |
| Fresenius USA Marketing, Inc. | 3 | $48 |
| Ardelyx, Inc. | 2 | $48 |
| GSK | 3 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $39 |
| Baxter Healthcare | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nephrology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 38 | $138,861 |
| AuryxiaFerric Citrate | 69 | $136,384 |
| VelphoroSucroferric Oxyhydroxide | 55 | $129,313 |
| TrulicityDulaglutide | 47 | $62,464 |
| FarxigaDapagliflozin Propanediol | 39 | $51,988 |
| JardianceEmpagliflozin | 55 | $47,107 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $46,973 |
| EliquisApixaban | 74 | $43,121 |
| MounjaroTirzepatide | 32 | $38,891 |
| Sevelamer Carbonate | 162 | $37,640 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $37,075 |
| EntrestoSacubitril/Valsartan | 40 | $35,682 |
| KerendiaFinerenone | 19 | $33,287 |
| TradjentaLinagliptin | 53 | $31,125 |
| OzempicSemaglutide | 20 | $26,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $48 | $129,31355 claims |
| AstraZenecaFarxiga, Lokelma | $181 | $98,96288 claims |
| PfizerEliquis | $219 | $43,12174 claims |
| NovartisEntresto | $335 | $35,68240 claims |
| BayerKerendia | $90 | $33,28719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nephrology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other nephrology in Anchorage
- Mark SmithAnchorage$150K
- Andrzej MaciejewskiAnchorage$60K
- Jeremy GitomerAnchorage$21K
- Shuang Ying BaoAnchorage$893
- Leslie GlasgowAnchorage$834
- Lisa RobertsAnchorage$681
- Rahul AbrahamAnchorage$485
- Osman YilmamAnchorage$412
- Chadwick BarnesAnchorage$224
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.